506 related articles for article (PubMed ID: 18062275)
1. [Construction and immunogenicity of an attenuated mutant of Actinobacillus pleuropneumoniae by insertional inactivation of apxIC].
Xu FZ; Shi AH; Chen XL; Yang B; Wang JL
Wei Sheng Wu Xue Bao; 2007 Oct; 47(5):923-7. PubMed ID: 18062275
[TBL] [Abstract][Full Text] [Related]
2. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
[TBL] [Abstract][Full Text] [Related]
3. Potential use an Actinobacillus pleuropneumoniae double mutant strain DeltaapxIICDeltaapxIVA as live vaccine that allows serological differentiation between vaccinated and infected animals.
Liu J; Chen X; Lin L; Tan C; Chen Y; Guo Y; Jin M; Guo A; Bei W; Chen H
Vaccine; 2007 Nov; 25(44):7696-705. PubMed ID: 17767980
[TBL] [Abstract][Full Text] [Related]
4. Construction and immunogencity of a DeltaapxIC/DeltaapxIIC double mutant of Actinobacillus pleuropneumoniae serovar 1.
Lin L; Bei W; Sha Y; Liu J; Guo Y; Liu W; Tu S; He Q; Chen H
FEMS Microbiol Lett; 2007 Sep; 274(1):55-62. PubMed ID: 17608699
[TBL] [Abstract][Full Text] [Related]
5. [Construction and characterization of Actinobacillus pleuropneumoniae serovar 7 live attenuated vaccine strain co-expressing ApxIA].
Liu J; Chen Y; Hu L; Bei W; Chen H
Sheng Wu Gong Cheng Xue Bao; 2010 Mar; 26(3):305-10. PubMed ID: 20518341
[TBL] [Abstract][Full Text] [Related]
6. Construction and characterization of a live, attenuated apxIICA inactivation mutant of Actinobacillus pleuropneumoniae lacking a drug resistance marker.
Bei W; He Q; Yan L; Fang L; Tan Y; Xiao S; Zhou R; Jin M; Guo A; Lv J; Huang H; Chen H
FEMS Microbiol Lett; 2005 Feb; 243(1):21-7. PubMed ID: 15667996
[TBL] [Abstract][Full Text] [Related]
7. Construction and immunogenicity of a ∆apxIC/ompP2 mutant of Actinobacillus pleuropneumoniae and Haemophilus parasuis.
Liu Q; Gong Y; Cao Y; Wen X; Huang X; Yan Q; Huang Y; Cao S
Onderstepoort J Vet Res; 2013 Mar; 80(1):519. PubMed ID: 23718128
[TBL] [Abstract][Full Text] [Related]
8. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
9. [Construction and characterization of an attenuate strain apxIC-/P36+ of Actinobacillus pleuropneumoniae serovar 10].
Zou H; Chen Y; Liu X; He Q; Chen P; Zhou R; Ma F; Wang Y
Wei Sheng Wu Xue Bao; 2009 Sep; 49(9):1209-16. PubMed ID: 20030060
[TBL] [Abstract][Full Text] [Related]
10. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
[TBL] [Abstract][Full Text] [Related]
11. Risk assessment of transmission of capsule-deficient, recombinant Actinobacillus pleuropneumoniae.
Inzana TJ; Glindemann G; Fenwick B; Longstreth J; Ward D
Vet Microbiol; 2004 Nov; 104(1-2):63-71. PubMed ID: 15530740
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model.
Chiang CH; Huang WF; Huang LP; Lin SF; Yang WJ
Vaccine; 2009 Jul; 27(34):4565-70. PubMed ID: 19520199
[TBL] [Abstract][Full Text] [Related]
13. Deletion of the znuA virulence factor attenuates Actinobacillus pleuropneumoniae and confers protection against homologous or heterologous strain challenge.
Yuan F; Liao Y; You W; Liu Z; Tan Y; Zheng C; BinWang ; Zhou D; Tian Y; Bei W
Vet Microbiol; 2014 Dec; 174(3-4):531-539. PubMed ID: 25465668
[TBL] [Abstract][Full Text] [Related]
14. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
[TBL] [Abstract][Full Text] [Related]
15. Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence.
Boekema BK; Kamp EM; Smits MA; Smith HE; Stockhofe-Zurwieden N
Vet Microbiol; 2004 May; 100(1-2):17-23. PubMed ID: 15135509
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs.
Bei W; He Q; Zhou R; Yan L; Huang H; Chen H
Vet Microbiol; 2007 Nov; 125(1-2):120-7. PubMed ID: 17580102
[TBL] [Abstract][Full Text] [Related]
17. Attenuated Actinobacillus pleuropneumoniae double-deletion mutant S-8∆clpP/apxIIC confers protection against homologous or heterologous strain challenge.
Xie F; Li G; Zhou L; Zhang Y; Cui N; Liu S; Wang C
BMC Vet Res; 2017 Jan; 13(1):14. PubMed ID: 28061786
[TBL] [Abstract][Full Text] [Related]
18. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon.
Prideaux CT; Lenghaus C; Krywult J; Hodgson AL
Infect Immun; 1999 Apr; 67(4):1962-6. PubMed ID: 10085043
[TBL] [Abstract][Full Text] [Related]
19. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination.
Prideaux CT; Pierce L; Krywult J; Hodgson AL
Curr Microbiol; 1998 Nov; 37(5):324-32. PubMed ID: 9767712
[TBL] [Abstract][Full Text] [Related]
20. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine.
Tonpitak W; Baltes N; Hennig-Pauka I; Gerlach GF
Infect Immun; 2002 Dec; 70(12):7120-5. PubMed ID: 12438394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
